EUCTR2010-021039-14-FI进行中（未招募）不适用
An open-label, phase IV, pilot study, to evaluate confocal microscopic findings of cornea, ocular signs and symptoms in patients with ocular hypertension or open-angle glaucoma switching from latanoprost 0.005% (preserved) to preservative free tafluprost 0.0015% eye drops.
Tampere University, Faculty of Medicine, Department of Ophthalmology0 个研究点目标入组 30 人开始时间: 2010年6月29日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Have provided a written informed consent
- •2.Aged 18 years or more
- •3.A diagnosis of ocular hypertension or open-angle glaucoma (either POAG or capsular glaucoma) in one or both eyes, for which the patient has been regularly using latanoprost 0.005% (Xalatan®) for at least six months before Screening (confirmed in anamnesis).
- •4.In the Screening visit evaluation, the presence of:
- •At least two ocular symptoms considered for the two eyes together (irritation/burning/stinging, foreign body sensation, tearing, itching or dry eye sensation) of at least mild severity (grade = 2) upon non-instillation
- •One ocular symptom of at least mild severity (grade = 2) upon non-instillation AND at least one of the following ocular signs in either eye with prior treatment:
- •Fluorescein tear break-up time (fBUT): less than 10 seconds
- •Corneal and conjunctival fluorescein staining:
- •?Corneal fluorescein staining score of at least grade I OR
- •?Combined nasal and temporal staining scores of at least grade II
- •Blepharitis: of at least mild severity (grade = 1)
- •Conjunctival redness/hyperemia: of at least mild severity (grade 1)
- •Tear production: 10 mm or less on Schirmer test
- •5.A best corrected ETDRS visual acuity score of +0.6 logMAR or better in both eyes
- •6.Negave pregnancytest result at the screening visit, or, consistently and correctly used reliable method of contraception during the study
- •7.Are willing to follow instructions
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Females who are pregnant, nursing or planning a pregnancy, or females of childbearing potential who are not using a reliable method of contraception1
- •2.Anterior chamber angle in either eye to be treated less than grade 2 according to Schaffer classification as measured by gonioscopy
- •3.Any corneal abnormality or other condition preventing reliable applanation tonometry, including prior refractive eye surgery
- •4.IOP greater than 22 mmHg at 15:00 IOP measurement in either eye at Screening/Baseline visit
- •5.Use of preserved eye drops (other than latanoprost) including artificial tears at screening or within two weeks prior to screening visit
- •6.Diagnosis of angle-closure glaucoma or secondary glaucoma other than capsular glaucoma in either eye
- •7.Suspected contraindication to tafluprost therapy (hypersensitivity to tafluprost or any of the excipients).
- •8.Glaucoma filtration surgery or any other ocular surgery (including ocular laser procedures) within 6 months prior to Screening in eye(s) to be treated with study medication
- •9.Use of contact lenses at Screening or during the study
- •10.Any ocular (e.g. aphakia, pseudophakia with torn posterior lens capsule2 or anterior chamber lenses, known risk factors for cystoid macular oedema or iritis/uveitis), systemic or psychiatric disease/condition (e.g. uncontrolled arterial hypertension, diabetes) that may put the patient at a significant risk or may confound the study results or may interfere significantly with the patient’s participation in the study as judged by the investigator
- •11.Current alcohol or drug abuse
- •12.Current participation in another clinical trial involving an investigational drug/device, or participation in such a trial within the last 30 days
研究者
相似试验
已完成
4 期
Open label clinical trial to evaluate safety and tolerability of FDC of Ebastine (10 mg) and Phenylephrine (10 mg)CTRI/2018/08/015262Sterling Lab145
已完成
不适用
ong-term follow-up of children who participated at 9-12 months of age in clinical trial PsA-TT-007 in MaliMeningococcal serogroup AInfections and InfestationsISRCTN37623829PATH825
进行中（未招募）
1 期
Afatinib as second-line therapy for lung cancer with EGFR mutatioMetastatic non-small cell lung cancer harbouring an EGFR mutation (Del 19 or L858R)MedDRA version: 19.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001077-14-PLBoehringer Ingelheim RCV GmbH & Co KG282
进行中（未招募）
1 期
Afatinib as second-line therapy for lung cancer with EGFR mutatioMetastatic non-small cell lung cancer harbouring an EGFR mutation (Del 19 or L858R)MedDRA version: 17.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001077-14-ROBoehringer Ingelheim RCV GmbH & Co KG70
招募中
2 期
Study to evaluate the efficacy of Sucralfate as a healing agent in bed sores.CTRI/2016/03/006745Internal FLUID Grant Christian Medical College Vellore30